SOS1 is altered in 4.21% of melanoma patients [3].

SOS1 is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains SOS1 status and melanoma as inclusion criteria, 1 is phase 1 (1 open) [4].

SOS1 is altered in 2.9% of ganglioglioma patients [3].

SOS1 is an inclusion criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains SOS1 status and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

SOS1 is altered in 2.64% of astrocytic tumor patients [3].

SOS1 is an inclusion criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains SOS1 status and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

SOS1 is altered in 2.57% of diffuse glioma patients [3].

SOS1 is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains SOS1 status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

SOS1 is altered in 1.85% of non-small cell lung carcinoma patients [3].

SOS1 is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SOS1 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

SOS1 is altered in 1.87% of malignant solid tumor patients [3].

SOS1 is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains SOS1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [4].

SOS1 is altered in 1.54% of neuronal and mixed neuronal-glial tumors patients [3].

SOS1 is an inclusion criterion in 1 clinical trial for neuronal and mixed neuronal-glial tumors, of which 1 is open and 0 are closed. Of the trial that contains SOS1 status and neuronal and mixed neuronal-glial tumors as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

SOS1 is altered in 0.85% of pilocytic astrocytoma patients [3].

SOS1 is an inclusion criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains SOS1 status and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

SOS1 is altered in 0.94% of low grade glioma patients [3].

SOS1 is an inclusion criterion in 1 clinical trial for low grade glioma, of which 1 is open and 0 are closed. Of the trial that contains SOS1 status and low grade glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

SOS1 is an inclusion criterion in 1 clinical trial for dysembryoplastic neuroepithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains SOS1 status and dysembryoplastic neuroepithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

SOS1 is an inclusion criterion in 1 clinical trial for gangliocytoma, of which 1 is open and 0 are closed. Of the trial that contains SOS1 status and gangliocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

SOS1 is an inclusion criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains SOS1 status and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

SOS1 is an inclusion criterion in 1 clinical trial for pilomyxoid astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains SOS1 status and pilomyxoid astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].